Galectin Therapeutics
GALT
GALT
79 hedge funds and large institutions have $26.8M invested in Galectin Therapeutics in 2024 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.34% more ownership
Funds ownership: 15.32% → 15.65% (+0.34%)
29% less call options, than puts
Call options by funds: $3.89M | Put options by funds: $5.46M
Holders
79
Holding in Top 10
–
Calls
$3.89M
Puts
$5.46M
Top Buyers
| 1 | +$387K | |
| 2 | +$295K | |
| 3 | +$154K | |
| 4 |
BlackRock
New York
|
+$119K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$117K |
Top Sellers
| 1 | -$332K | |
| 2 | -$156K | |
| 3 | -$146K | |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$112K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$90.5K |